Arvinas (NASDAQ:ARVN) & SELLAS Life Sciences Group (NASDAQ:SLS) Financial Contrast

SELLAS Life Sciences Group (NASDAQ:SLSGet Free Report) and Arvinas (NASDAQ:ARVNGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Volatility & Risk

SELLAS Life Sciences Group has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Valuation and Earnings

This table compares SELLAS Life Sciences Group and Arvinas’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SELLAS Life Sciences Group $1.00 million 86.05 -$37.34 million ($1.10) -1.35
Arvinas $78.50 million 22.05 -$367.30 million ($5.93) -4.27

SELLAS Life Sciences Group has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SELLAS Life Sciences Group and Arvinas’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SELLAS Life Sciences Group N/A -5,258.30% -249.95%
Arvinas -185.09% -64.79% -30.46%

Institutional & Insider Ownership

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 1.6% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 5.2% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for SELLAS Life Sciences Group and Arvinas, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group 0 0 1 0 3.00
Arvinas 0 2 14 0 2.88

SELLAS Life Sciences Group presently has a consensus price target of $3.00, indicating a potential upside of 101.34%. Arvinas has a consensus price target of $61.13, indicating a potential upside of 143.37%. Given Arvinas’ higher possible upside, analysts clearly believe Arvinas is more favorable than SELLAS Life Sciences Group.

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

About Arvinas

(Get Free Report)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.